Dr Nicholas Coltman and Professor Ruth Roberts are co-organising the Science-led Strategies for Success in Discovery & Development Toxicology on Wednesday 15th June 2022 at the Alderley Park Conference Centre in Cheshire. ApconiX is co-organising the event with the British Society of Toxicology, Alderley Park, AstraZeneca, Sygnature Discovery, GlaxoSmithKline and UCB.
The event is free to attend. Register here: Science-led Strategies for Success in Discovery & Development Toxicology.
Ruth Roberts will be giving the opening address “Challenges and Opportunities in Drug Discovery” and other speakers include Professor Dean Naisbitt, Senior Lecturer, Pharmacology & Therapeutics in the MRC funded Centre for Drug Safety Science at the University of Liverpool, Susanne Moore, Scientific Director, Nonclinical Safety Projects at GSK, Jean-Pierre Valentin, Senior Director, Head of Investigative Toxicology at UCB and Sonja Gill, Discovery Safety Specialist and Bone Marrow Safety Strategy Lead at AstraZeneca.
Nicholas, who joined ApconiX in January this year, commented, “It has been great to get involved with this event, having previously been involved in 2016 when the meeting was hosted by Sygnature Discovery at BioCity, Nottingham.”
“As an early career toxicologist, myself, my co-organisers and I have tried to make this one-day event as accessible as possible, to both junior scientists and experienced stakeholders within the pharmaceutical industry. My own journey through regulatory toxicology, academia, pharmaceutical research and back-again, exemplifies the need to nurture early career toxicologists through the British Toxicology Society. It has been a great opportunity to work alongside my esteemed colleagues at AstraZeneca, Sygnature Discovery, GlaxoSmithKline and UCB to bring this event to fruition!”
Safety risks are a major cause of attrition in drug discovery and development. A well designed and delivered toxicology package together with prompt and robust problem solving can make the difference between success and failure.
With advances in novel in vitro and in silico methodologies along with the greater understanding of the underlying mechanisms and biomarkers, discovery toxicology has emerged as a fundamental aspect of early-stage R&D and is now recognized as a key step to build for success later in drug development.
The meeting will showcase strategies that are enabling more efficient and robust approaches to achieve success in drug discovery and development and will be of interest to colleagues from all aspects of drug discovery and related disciplines.